EMA Validates Marketing Authorization Application for Trastuzumab Duocarmazine (SYD985) in HER2-Positive Metastatic Breast Cancer

/PRNewswire/ -- Byondis B.V., an independent, Dutch clinical stage biopharmaceutical company creating precision medicines, announced today that the European...

Related Keywords

United Kingdom ,Germany ,Norway ,Iceland ,Netherlands ,Liechtenstein ,Switzerland ,Nijmegen ,Gelderland ,Dutch ,Prnewswire Byondis ,Marco Timmers ,Trastuzumab Duocarmazine ,Drug Technology ,Us Food Drug Administration ,European Medicines Agency ,Regulatory Agency ,Submission Follows Positive Results ,Byondis Technologies Aimed ,Improving Treatment Outcomes ,Marketing Authorization Application ,European Economic Area ,Managing Director ,Drug Administration ,United Kingdom Medicines ,Next Generation Antibody Drug ,Byondi Distinctive ,Proprietary Linker Drug ,Good Manufacturing Practice ,Byondisbv ,